 ImmunoPrecise Antibodies Ltds NASDAQ: IPA subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization. The target is a protein receptor that is overexpressed in a variety of types of deadly cancers. 